Novacyt S.A. Primerdesign partners with VGS Group in France (0936A)
17 Enero 2020 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 0936A
Novacyt S.A.
17 January 2020
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Primerdesign partners with
VGS Group in France
Commercial agreement includes molecular diagnostics for the
growing aquaculture and aquamarine market
Paris, France and Camberley, UK - 17 January 2020 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces its molecular testing division,
Primerdesign Ltd ("Primerdesign"), has signed an exclusive
commercial agreement with Atothis SARL, part of VGS Invest Holding
Sarl Group ("VGS Group"), for the distribution of certain molecular
diagnostic products in France for the growing aquaculture and
aquamarine markets. France is the second largest aquaculture
producer in the EU, with shellfish production alone contributing a
total of 155,000 tonnes a year valued at approximately EUR550
million to the French economy.
The distribution partnership combines the commercial strength of
the VGS Group, with Primerdesign's innovative molecular genesig(R)
diagnostic tests and the Company's proprietary q16 instrument.
Primerdesign's diagnostic products will be used for the early
identification of diseases impacting animal health during food
production. The agreement has an initial term of three years and
commits VSG to purchase a minimum of EUR690,000 of Primerdesign
products.
The VGS Group, which trades as the Antinea Group, is the largest
independent distributor of aquamarine products in France. The
Antinea Group was founded in 1991 and has grown significantly
during this period and employs over 70 personnel dedicated to the
French market.
Valery Perinet, CEO of the VGS Group, commented: "I am delighted
to have reached agreement with Novacyt for the aquamarine market in
France. After evaluating the extensive Primerdesign product range,
we are convinced this partnership will create significant value for
both companies in a market which is growing rapidly. My company,
with its strong and respected brand and distribution channels,
coupled with the innovative and high performing Primerdesign
products, should enable us to rapidly penetrate the French
market."
Graham Mullis, Group CEO of Novacyt, added: "As the largest
independent aquamarine distributor in France, VGS Group is an ideal
partner for Novacyt in this growing area. In addition, as a leading
aquaculture producer in the EU, France represents a significant
market opportunity for Novacyt. This important agreement reinforces
our previously identified organic growth strategy, which includes
focusing on strategic partners in the animal testing market. We
continue to focus on making our extensive range of molecular
products available to multiple markets through the appointment of
strategic partners in key territories. I look forward to updating
the market with additional partnerships as we expand our sales
channels."
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Cosme Julien Madoni
+33 (0)1 47 03 69 48 / +33 (0)147 03 68 19
arnaud.decheffontaines@fticonsulting.com /
cosme.julienmadoni@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
About VGS Invest Holding Sarl Group
The Antinea Group was founded in 1991 near Montpellier and is
owned by VGS Invest Holding Sarl Group. The Group has a turnover of
12 million euros with 70 over employees and consists of several
companies, focused on various segments of the French market. The
Group has access to a customer portfolio of 2,000 accounts
including pet retailers, public aquariums, aquatic fisheries and
aqua farms.
For more information please refer to the website:
www.groupe-antinea.fr
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGREAPFKFDEEEFA
(END) Dow Jones Newswires
January 17, 2020 02:00 ET (07:00 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024